Ibogaine

This article was originally published on Microdose and appears here with permission. Psychedelic research is becoming the future of mental health, with more and more studies showing their effectiveness in the treatment of mood disorders. Psychedelics like psilocybin, DMT, and ibogaine...

MindMed Inc. (NASDAQ: MNMD) reported favorable results for one of its proprietary compounds. The Phase 1 trial of MM-110 included 108 healthy volunteers and was designed to study the pharmacokinetics and neurocognitive effects of the substance, ensuring its safety and tolerability. MM-110 is...

It’s earnings week in the psychedelics space, opening a new window into the financial situations of many companies in the sector. Atai, MindMed, Enveric, Mydecine and Filament Health all released their numbers for 2021, with positions varying between “very well-capitalized” to...

This article was originally published on Cannabis.net and appears here with permission. These days, the use of psychedelics and alternative medicine is rapidly growing once again. While there has always been a subculture, the use of psychedelics hasn’t been as mainstream...

This article was originally published on The Bluntness and appears here with permission. New discoveries about what psychedelics do inside the human brain to help treat depression, PTSD, addiction, dementia and even phantom limb pain are coming fast and furious as...

This article was originally published on Microdose and appears here with permission. MindMed ended its 2021 news cycle on a somewhat mehhh note. In late December we reported that the FDA has put a hold on MindMed’s submission for its Phase 2b trial of LSD for the treatment...

The U.S. government has taken a significant step toward tackling the mounting national substance addiction crisis by partnering with neuroscience company Delix Therapeutics to study a non-hallucinogenic version of the psychedelic drug ibogaine.   Collaboration with the National Institute...

Novamind Inc. (OTCQB: NVMDF) a mental health company specializing in psychedelic medicine, recently announced a strategic investment and advisory agreement with Bienstar Wellness Corp, an Uruguay-based mental health company, to assist in the expansion of Latin America's first network of...

Psychedelic use may provide a window of opportunity to kick drug addiction, according to a recent study. Following bleak mortality data published this week by the U.S. Centers for Disease Control that saw national overdose deaths exceeding 100,000 for the first time over a 12 month period, a new...

A bill to decriminalize psychedelic substances in California is quickly moving up the legislative ladder. Introduced in February by Sen. Scott Wiener, SB 519 would remove penalties for the possession, personal use and social sharing of certain natural and synthetic psychoactive drugs...

Inside of a Legal Psilocybin Wellness Retreat At Benzinga, we do what we say, and we say what we do. This hands-on mentality allowed me to take a week off to experience a legal psilocybin retreat in Jamaica. The active ingredient in “magic mushrooms” is currently being researched by top...

Mind Cure Health Inc. (CSE: MCUR), a mental health and wellness company working in the psychedelics sector, announced the closing of a CA$23 Million ($18.1 million) offering. The company issued approximately 38 million units, consisting of one share and one half of a share purchase warrant, at CA$0...

District of Columbia To Include Psychedelics Decriminalization Measure on November Ballot The District of Columbia will likely become the nation’s second jurisdiction to include a psychedelics decriminalization measure in November. Oregon made a similar announcement last week, and will...

The Canadian NEO Exchange announced Tuesday that neuro-pharmaceutical company Mind Medicine Inc. (OTC:MMEDF) (NEO: MMED) will make its public market debut under the symbol "MMED." The exchange's approval of MindMed makes it the first psychedelic company to be publicly listed,...

After being fired from his position as CEO of Canopy Growth (NYSE: CGC) in July 2019, Bruce Linton spent the better part of last year giving speeches and making new connections. In a conversation with Benzinga in November, Linton, now executive chairman of Vireo Health International (OTC: VREOF)...